Immunome Inc (NASDAQ: IMNM)’s stock price has gone rise by 3.68 in comparison to its previous close of 15.50, however, the company has experienced a 9.25% increase in its stock price over the last five trading days. businesswire.com reported 2024-08-29 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations.
Is It Worth Investing in Immunome Inc (NASDAQ: IMNM) Right Now?
Moreover, the 36-month beta value for IMNM is 1.78. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMNM is 49.02M and currently, short sellers hold a 27.11% of that float. On September 19, 2024, IMNM’s average trading volume was 792.47K shares.
IMNM’s Market Performance
IMNM stock saw an increase of 9.25% in the past week, with a monthly gain of 5.65% and a quarterly increase of 27.74%. The volatility ratio for the week is 6.52%, and the volatility levels for the last 30 days are 6.66% for Immunome Inc (IMNM). The simple moving average for the last 20 days is 7.33% for IMNM’s stock, with a simple moving average of 0.95% for the last 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Piper Sandler repeating the rating for IMNM by listing it as a “Overweight.” The predicted price for IMNM in the upcoming period, according to Piper Sandler is $27 based on the research report published on May 31, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $24. The rating they have provided for IMNM stocks is “Overweight” according to the report published on April 30th, 2024.
Guggenheim gave a rating of “Buy” to IMNM, setting the target price at $35 in the report published on April 15th of the current year.
IMNM Trading at 11.58% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.09% of loss for the given period.
Volatility was left at 6.66%, however, over the last 30 days, the volatility rate increased by 6.52%, as shares surge +5.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.49% upper at present.
During the last 5 trading sessions, IMNM rose by +8.53%, which changed the moving average for the period of 200-days by +104.68% in comparison to the 20-day moving average, which settled at $15.01. In addition, Immunome Inc saw 50.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from BIENAIME JEAN JACQUES, who purchase 7,000 shares at the price of $13.94 back on Aug 16 ’24. After this action, BIENAIME JEAN JACQUES now owns 16,615 shares of Immunome Inc, valued at $97,608 using the latest closing price.
Higgins Jack, the Chief Scientific Officer of Immunome Inc, sale 3,524 shares at $13.93 during a trade that took place back on Aug 15 ’24, which means that Higgins Jack is holding 16,000 shares at $49,072 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -25.18 for the present operating margin
- 0.87 for the gross margin
The net margin for Immunome Inc stands at -24.35. The total capital return value is set at -1.06. Equity return is now at value -199.56, with -155.54 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -21.88. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1351.21.
Currently, EBITDA for the company is -108.8 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of 75.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.12.
Conclusion
To wrap up, the performance of Immunome Inc (IMNM) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
